Research led by EMBL Australia group leader Max Cryle has revealed a key aspect of peptide machineries, advancing his work in countering the global threat of antimicrobial resistance and having broad implications for health and industry.
Research led by EMBL Australia group leader Dr Harald Janovjak has revealed the potential of optogenetics - a relatively new and rapidly evolving technology - to treat Parkinson's disease.
Farewell to world-leading immunologist and molecular microscopist Scientia Professor Katharina Gaus - a visionary scientist, inspirational mentor, and much-loved friend, colleague and collaborator.
An exciting discovery by Monash University scientists - including members of EMBL Australia's leadership team, Professor Peter Currie and Associate Professor Mikaël Martino - may lead to faster recovery from muscle injury and wasting diseases.
We are excited to welcome the newest member of the EMBL Australia Council, Professor Ian Smith, who replaced the outgoing Professor Brandon Wainwright AM as chairperson, in November 2020.
A new detection method co-developed by EMBL Australia group leader Dr Yann Gambin could enable the early and accurate detection of Parkinson’s disease, vastly improving patient outcomes.
An international study co-led by EMBL Australia group leader Dr Yann Gambin has revealed a potential mechanism the SARS-CoV-2 virus may use to try to temper the host’s innate immune defence.
A clinical human trial of malaria infection led by EMBL Australia group leader Dr Michelle Boyle has linked the activation of specific immune cells to the induction of protective antibodies against malaria - an important step towards the development of an effective vaccine.
Three EMBL Australia group leaders have been awarded NHMRC Ideas Grants to expand their research in malaria, cancer cell biology and antibiotic resistance.
